



**PRESS RELEASE**

For Immediate Release

## **CardioVere®, A ChemImage Company, Accepted to Present Latest Clinical Trial Results at Heart Failure Society of America Annual Meeting**

*Evaluation Of Lower Extremity Congestion: A Validation Study Compared To MRI*

**PITTSBURGH, Pennsylvania, August 10, 2022** — CardioVere®, a ChemImage Company and an innovator in non-contact fluid measurement, is pleased to announce that their abstract **“Non-contact Molecular Chemical Imaging For Evaluation Of Lower Extremity Congestion: A Validation Study Compared To MRI”** has been accepted for presentation at the Heart Failure Society of America (HFSA) 2022 Annual Scientific Meeting in Washington, DC.

The HFSA Annual Scientific Meeting features the latest in diagnosis, management, and late-breaking clinical data related to heart failure. It brings the best of science, research, and practical management to healthcare professionals all in one place. To learn more: <https://hfsa.org/hfsa-annual-scientific-meeting-2022>.

CardioVere® seeks to be the next generation of tissue congestion measurement to help screen, monitor, and manage heart failure patients. Our HFSA presentation will feature the results of a clinical study done in collaboration with the Minneapolis Heart Institute Foundation and the Mayo Clinic comparing our patented Molecular Chemical Imaging (MCI) technology to MRI when evaluating lower extremity congestion. CardioVere’s parent company, ChemImage, is a pioneer in MCI with 28 years of experience in materials analysis and advanced clinical imaging.

"We are thrilled to be recognized by the Heart Failure Society of America for this innovative work and the potential it has to positively impact heart failure patients," said Dr. Adam Saltman, Chief Medical Officer of ChemImage, CardioVere’s parent company. "CardioVere technology is being compared for the first time against a gold standard reference method, MRI, and it will establish an important basis for CardioVere® to address unmet clinical needs in heart failure management."

###

### **About CardioVere®**

CardioVere® is designed to enable personalized care with the goal of detecting sub-clinical and clinical tissue congestion non-invasively across all care settings, including the home. Our mission is to provide precise information early in the heart failure decompensation cycle to improve patient care. CardioVere leverages proven, patented molecular chemical imaging technology developed by its parent company, ChemImage. The technology uses light, filters, and optics paired with our proprietary artificial intelligence algorithms and software enabling the user to see the unseen. <https://cardiovere.com/>



## **PRESS RELEASE**

For Immediate Release

### **About ChemImage Corporation**

ChemImage is committed to empowering the world with real-time autonomous smart chemical imaging technology to enhance users' situational awareness and decision making. The company's proprietary, state-of-the-art chemical imaging sensors, algorithms, and computer vision analysis software empower medical device, pharmaceutical and life science companies, as well as security and law enforcement professionals, to take on challenging health and safety needs with the Awareness of Things® (AoT®). With performance leading chemical imaging technology and advanced software and algorithms, ChemImage strives to bring a new level of situational awareness to people in their everyday lives.

[www.chemimage.com](http://www.chemimage.com).

### **Media Contact**

Veronica Rillo, Director of Marketing Communications

Office: (412) 241-7335 x269

Mobile: (801) 656-7084

Email: [rillov@chemimage.com](mailto:rillov@chemimage.com)